Prothena director granted 27,000 stock options

PROTHENA CORP PUBLIC LTD CO director Richard T. Collier received a grant of stock options covering 27,000 ordinary shares.

Accepted by SEC EDGAR 05/15/2026 - 09:28 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PROTHENA CORP PUBLIC LTD CO director Richard T. Collier received a grant of stock options covering 27,000 ordinary shares. The options have an exercise price of $9.76 per share and expire on May 15, 2036. According to the award terms, all 27,000 options will vest and become exercisable on the earlier of the first anniversary of the May 15, 2026 grant date or the day of Prothena’s 2027 annual general meeting, provided he continues to serve as a director through that vesting date.

Insider Trade Summary

Grant/Award: 27,000 shares

Grant/Award 1 txn

Insider COLLIER RICHARD T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	27,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 27,000 contracts (Direct)

Footnotes (1)

F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

Key Figures

Options granted: 27,000 options Exercise price: $9.76 per share Expiration date: May 15, 2036 +1 more

4 metrics

Options granted 27,000 options Stock Option (Right to Buy) awarded to director

Exercise price $9.76 per share Exercise price for 27,000 stock options

Expiration date May 15, 2036 Option term end date

Underlying shares 27,000 ordinary shares Shares underlying the stock option grant

Key Terms

Stock Option (Right to Buy), Ordinary Shares, Grant, award, or other acquisition, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "9.7600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prothena (PRTA) director Richard T. Collier report on this Form 4?

Richard T. Collier reported receiving a grant of stock options for 27,000 ordinary shares of Prothena. These options were awarded as director compensation and are not an open-market purchase or sale of the company’s stock.

What are the key terms of Richard T. Collier’s Prothena (PRTA) stock option grant?

The grant covers 27,000 ordinary shares with an exercise price of $9.76 per share and an expiration date of May 15, 2036. These terms define the price he must pay to exercise and the latest date he can do so.

When do Richard T. Collier’s Prothena (PRTA) options vest and become exercisable?

All 27,000 options vest on the earlier of the first anniversary of the May 15, 2026 grant date or the 2027 annual general meeting. Vesting is contingent on his continuous service as a director until that vesting date.

Is Richard T. Collier buying or selling Prothena (PRTA) shares in this Form 4?

This filing shows a stock option grant, not a market transaction. Collier is receiving options as compensation, which may later be exercised to acquire shares at $9.76, but no shares were bought or sold in the market here.

How many Prothena (PRTA) derivative securities does Richard T. Collier hold after this grant?

After this transaction, Collier holds 27,000 stock options as reported in the filing. These options each relate to one ordinary share and represent his current derivative position from this specific award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COLLIER RICHARD T

(Last)

(First)

(Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.76	05/15/2026		A		27,000		⁽¹⁾	05/15/2036	Ordinary Shares	27,000	$0	27,000	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2027 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.

	/s/ Michael J. Malecek, as Attorney-in-Fact for Richard T. Collier	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR